Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
This is a comparative, conceptual, randomized clinical study to investigate newly developed
over basic Echinacea formulations for the treatment of acute symptoms of respiratory tract
infections. 400 adults will be recruited, of which approximately 300 will develop a common
cold or a influenza-like infection. Two newly developed and two existing Echinacea
formulations (solid/liquid) will be randomly dispensed at inclusion for treatment of maximal
3 infections. Treatment starts at first signs of infection and lasts for a maximum of 10 days
or until symptom resolution. Nasopharynx samples will be collected for analysis of common
viral respiratory agents throughout treatment. Safety and efficacy variables will be
assessed.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
A. Vogel AG Bioforce AG
Collaborators:
Cantonal Hospital of St. Gallen Labormedizinisches Zentrum Dr. Risch